Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun 16;27(1):63.
doi: 10.1186/s10020-021-00321-3.

Immersion in the search for effective cancer immunotherapies

Steven A Rosenberg  1
Affiliations
Editorial

Immersion in the search for effective cancer immunotherapies

Steven A Rosenberg. Mol Med. .

Erratum in

No abstract available

Keywords: Adoptive transfer; Cancer; Immunotherapy; Lymphocytes; T-cells.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
With the first patient to respond to IL-2 administration. Her metastatic melanoma underwent a complete regression in 1984 and she remains disease-free over 36 years later
Fig. 2
Fig. 2
Examples of the earliest complete responses to IL-2 administration that ultimately led to the first FDA approval of a cancer immunotherapy (upper panels, melanoma; lower panels, renal cancer)
Fig. 3
Fig. 3
One of many discussions I had with W. French Andersen and Michael Blaese in 1989 as we planned and conducted the first introduction of a foreign gene into humans
Fig. 4
Fig. 4
In weekly laboratory meetings (this one in 1998) of all members of my group including scientists, clinical fellows, technicians, students and nurses. Fellows presented their ongoing research designed to receive input and keep all up-to-date on clinical and laboratory efforts
Fig. 5
Fig. 5
Senior members of the Surgery Branch in 2001. Front row: Patrick Hwu, Suzanne L Topalian, Steven A. Rosenberg, H. Richard Alexander, James C. Yang; Second row: David S. Schrump, Dao Nguyen, David N. Danforth, Steven K. Libutti, David L. Bartlett. Douglas J. Schwartzentruber; Third row: Richard A. Morgan, Paul F. Robbins, Nicholas P. Restifo, John R. Wunderlich
Fig. 6
Fig. 6
Immunotherapy staff in the Surgery Branch in 2006. Front row: Ken-ichi Hanada, Nicholas P. Restifo, Maria R. Parkhurst, Mark E. Dudley. Second row: Luca Gattinoni, Paul F. Robbins, James C. Yang, Steven A. Rosenberg, Richard M. Sherry, Richard A. Morgan, John R. Wunderlich, Steve A. Feldman. Inserts: Marybeth S. Hughes, Giao Q. Phan
Fig. 7
Fig. 7
One of many reunions of former fellows and staff of the Surgery Branch we had periodically starting in 1997 (shown here in 2013)
Fig. 8
Fig. 8
Photos line the walls outside my office dedicated to the hundreds of fellows who worked in my laboratory and make important contributions to our efforts
Fig. 9
Fig. 9
a CAT Scans of the first patient to respond to treatment (in 2009) with adoptive transfer of autologous lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD19 (left, lymphoma burden shown with arrows); right, complete cancer regression now ongoing over 10 years later. b In clinic with the first patient 10 years after treatment
See this image and copyright information in PMC

References

    1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116. doi: 10.1200/JCO.1999.17.7.2105. - DOI - PubMed
    1. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279–286. doi: 10.1038/nm827. - DOI - PubMed
    1. Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–3815. doi: 10.1200/JCO.20.01467. - DOI - PMC - PubMed
    1. Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J Immunol. 1981;126:1318–1322. - PubMed
    1. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol. 1983;130:2203–2208. - PubMed